Skip to Content


Generic Name: erenumab-aooe
Dosage Form: Injection, for Subcutaneous Use
Date of Approval: May 17, 2018
Company: Amgen Inc.

Treatment for: Migraine Prevention

FDA Approves Aimovig

The U.S. Food and Drug Administration (FDA) has approved Aimovig (erenumab-aooe), a calcitonin gene-related peptide (CGRP) receptor antagonist administered once-monthly for the preventive treatment of migraine.

Patient Information

Read this Patient Information carefully before you start treatment. This information does not take the place of talking with your doctor about your medical condition or your treatment.

What is Aimovig?

Aimovig is a prescription medicine used for the preventive treatment of migraine in adults.

It is not known if this medicine is safe and effective in children under 18 years of age.

Before you start treatment, tell your healthcare provider about all your medical conditions, including if you are:

  • Allergic to rubber or latex. The needle shield within the white cap of the single-dose prefilled SureClick autoinjectors and the gray needle cap of the single-dose prefilled syringes contain dry natural rubber.
  • Pregnant or plan to become pregnant. It is not known if Aimovig will harm your unborn baby.
  • Breastfeeding or plan to breastfeed. It is not known if Aimovig passes into your breast milk. You and your healthcare provider should decide if you will take Aimovig or breastfeed.

Tell your pharmacist or healthcare provider about all the medicines you take, including any prescription and over-the-counter medicines, vitamins, or herbal supplements.

How should I take Aimovig?

  • See the detailed Instructions for Use leaflet that comes with your prescription for complete information on how to use Aimovig.
  • Use Aimovig exactly as your healthcare provider tells you to take it.
  • Before you inject, always check the label of your single-dose prefilled autoinjector or single-dose prefilled syringe to make sure you have the correct medicine and the correct dose.
  • Aimovig is injected under your skin (subcutaneously) one time each month.
  • Aimovig is available in two different types of devices: a single-dose (1 time) prefilled autoinjector or a single-dose (1 time) prefilled syringe. Your healthcare provider will prescribe the type and dose that is best for you.
    • If your healthcare provider prescribes the 70 mg dose for you, take one injection.
    • If your healthcare provider prescribes the 140 mg dose for you, take two separate injections one after another, using a different prefilled autoinjector or prefilled syringe for each injection. If you want to use the same body site for the two separate injections, make sure the second injection it is not at the same spot you used for the first injection.
  • If you forget to take your dose or are not able to take the dose at the regular time, take your missed dose as soon as you remember. After that, you can continue to take Aimovig one time each month from the date of your last dose.

Aimovig side effects

The most common side effects include: pain, redness, or swelling at the injection site and constipation.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all of the possible side effects. Ask your pharmacist or healthcare provider for more information.

Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800- FDA-1088. You may also report side effects to Amgen at 1-800-77-AMGEN (1-800-772-6436).

How should I store Aimovig?

  • Store Aimovig in the refrigerator between 36°F to 46°F (2°C to 8°C).
  • Keep Aimovig in the original carton. This will protect the medicine from light.
  • After removing Aimovig from the refrigerator, it can be stored at room temperature between 68°F to 77°F (20°C to 25°C) for up to 7 days.
  • Throw away Aimovig that has been left at room temperature for more than 7 days.
  • Do not freeze.
  • Do not shake.

Keep all medicines out of the reach of children and pets.

General information about the safe and effective use of Aimovig.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use this medicine for a condition for which it is not prescribed. Do not give it to other people, even if they have the same symptoms that you have. It can harm them. You can ask your pharmacist or healthcare provider for information that is written for healthcare professionals.

What are the ingredients in Aimovig?

  • Active Ingredient: erenumab-aooe
  • Inactive Ingredients: acetate, polysorbate 80, and sucrose.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

More about Aimovig (erenumab)

Professional resources

Related treatment guides